Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02385279Not ApplicableCompleted

Study Comparing the MiStent SES Versus the XIENCE EES Stent

Role: collaborator

NCT02448524Phase 3Unknown

Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)

Role: lead

NCT03423511Not ApplicableNot Yet Recruiting

Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.

Role: lead

NCT02972671Not ApplicableUnknown

Trial of MiStent Compared to Xience in Japan

Role: lead

NCT01294748Phase 2Completed

Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease

Role: lead

NCT01247428Phase 2Completed

First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease

Role: lead

All 6 trials loaded